Lincoln Pharmaceuticals posts FY23 PAT at Rs. 72.90 Cr

For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year

JB Pharma records revenue growth of 22% to Rs. 762 Cr

Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23

Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023

Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr

The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year

IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr

Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23

RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr

Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23

PI Industries announces twin acquisitions into Pharma API & CDMO space

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects

Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr

The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023